In this ‘Patti’s People’ episode, Patti Peeples of the The Peeples Collaborative speaks with Jeremy Rassen, Co-founder & CEO, Aetion.
Note, this interview took place prior to the Datavant acquisition of Aetion.
Questions:
00:00: Introduction
00:32: Tell us about your career trajectory, and what your focus is now.
05:00: How do you define ‘regulatory-grade’ RWE at Aetion, and how does it differ from evidence used for publications or internal decisions?
09:25: Do you think we've overreached in using RWD, and, if so, in what areas?
12:10: What is Aetion doing to improve RWD quality?
17:44: How are you applying your AI background to data analytics in your current work?
23:41: With rising scrutiny around commercial influence in RWE, what role do public-interest audits, independent replication, or open protocols play at Aetion?
30:29: How is Aetion addressing missing public health data, and can commercial groups help fill these gaps for public benefit?
32:04: Which thinkers have influenced your views on uncertainty and evidence, and how do those ideas shape Aetion’s platform?
34:31: Rapid Fire Questions
Jeremy Rassen
Co-founder & CEO, Aetion
Dr Rassen is an epidemiologist and computer scientist with more than 25 years of experience in how causal inference and AI can drive understanding of the safety, effectiveness and value of medical treatments. He co-founded Aetion to pursue a vision of technology providing the speed, scale and rigor required to answer high-stakes questions in healthcare. Dr Rassen has overseen Aetion’s work with 18 of the 20 top global pharma companies, as well as many other customers around healthcare. During the COVID-19 pandemic, he initiated Aetion’s research collaborations with the US FDA and was a leading voice on how RWE could be applied to decisions around COVID-19 and other critical decisions in healthcare. Prior to Aetion, Dr Rassen was an assistant professor of medicine at Harvard Medical School, where he developed methods to improve the quality and validity of RWD studies. He started his career in Silicon Valley, where he was the first employee at E.piphany to join the company’s founders to build a novel, data-driven customer relationship management (CRM) platform and sell it to Fortune 50 companies. Dr Rassen received a Bachelor of Arts in Computer Science from Harvard University and a Doctor of Science in Epidemiology from the Harvard TH Chan School of Public Health. He is a fellow and board member of the International Society of Pharmacoepidemiology.
","author_name":"The Evidence Base"}